Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheng Hao

Showing results (1031-1040 of 1,049) with videos related to

Pageof 105
Sort By:
Gut|June 4, 2025
Differential HCC risk among HBV indeterminate types at baseline and by phase transitionRui Huang, Huy N Trinh, Satoshi Yasuda, et al.
Hepatology International|December 5, 2020
HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohortYasuhito Tanaka, Eiichi Ogawa, Chung-Feng Huang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 29, 2019
Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice ImplicationEiichi Ogawa, Hidenori Toyoda, Etsuko Iio, et al.
Hepatology International|August 30, 2019
Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C ConsortiumChung-Feng Huang, Etsuko Iio, Dae Won Jun, et al.
Alimentary Pharmacology & Therapeutics|January 4, 2024
Racial and ethnic disparities in untreated patients with hepatitis C virus-related hepatocellular carcinoma but not in those with sustained virologic responseJung Eun Park, Vy H Nguyen, Pei-Chien Tsai, et al.
Hepatology (Baltimore, Md.)|June 25, 2025
Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosisJie Li, Liang Xu, Fajuan Rui, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 21, 2023
Sex Differences in Treatment Response to Nucleos(t)ide Therapy in Chronic Hepatitis B: A Multicenter Longitudinal StudyAngela Chau, Ming-Lun Yeh, Pei-Chien Tsai, et al.
Alimentary Pharmacology & Therapeutics|May 21, 2025
Distribution, Characteristics, and Natural History of Diverse Types of Indeterminate Chronic Hepatitis B: A REAL-B StudyRui Huang, Ai-Thien Do, Hidenori Toyoda, et al.
Clinical and Molecular Hepatology|March 17, 2025
Impact of components of metabolic syndrome on long-term outcomes of CHB with nucleos(t)ide analogue treatmentRui Huang, Dae Won Jun, Hidenori Toyoda, et al.
Eclinicalmedicine|August 20, 2025
Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort studyRui Huang, Dae Won Jun, Hidenori Toyoda, et al.
Pageof 105

Showing results (1031-1040 of 1,049) with videos related to

Sort By:
Pageof 105
Gut|June 4, 2025
Differential HCC risk among HBV indeterminate types at baseline and by phase transitionRui Huang, Huy N Trinh, Satoshi Yasuda, et al.
Hepatology International|December 5, 2020
HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohortYasuhito Tanaka, Eiichi Ogawa, Chung-Feng Huang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 29, 2019
Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice ImplicationEiichi Ogawa, Hidenori Toyoda, Etsuko Iio, et al.
Hepatology International|August 30, 2019
Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C ConsortiumChung-Feng Huang, Etsuko Iio, Dae Won Jun, et al.
Alimentary Pharmacology & Therapeutics|January 4, 2024
Racial and ethnic disparities in untreated patients with hepatitis C virus-related hepatocellular carcinoma but not in those with sustained virologic responseJung Eun Park, Vy H Nguyen, Pei-Chien Tsai, et al.
Hepatology (Baltimore, Md.)|June 25, 2025
Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosisJie Li, Liang Xu, Fajuan Rui, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 21, 2023
Sex Differences in Treatment Response to Nucleos(t)ide Therapy in Chronic Hepatitis B: A Multicenter Longitudinal StudyAngela Chau, Ming-Lun Yeh, Pei-Chien Tsai, et al.
Alimentary Pharmacology & Therapeutics|May 21, 2025
Distribution, Characteristics, and Natural History of Diverse Types of Indeterminate Chronic Hepatitis B: A REAL-B StudyRui Huang, Ai-Thien Do, Hidenori Toyoda, et al.
Clinical and Molecular Hepatology|March 17, 2025
Impact of components of metabolic syndrome on long-term outcomes of CHB with nucleos(t)ide analogue treatmentRui Huang, Dae Won Jun, Hidenori Toyoda, et al.
Eclinicalmedicine|August 20, 2025
Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort studyRui Huang, Dae Won Jun, Hidenori Toyoda, et al.
Pageof 105